EGFR-TKIs在晚期肺腺鳞癌患者的疗效分析  

Analysis on the Curative Effect of EGFR-TKIs in the Treatment of Advanced Adenosquamous Carcinoma of the Lung

作　　者：曹燕青 王希成[1] 彭苗[1] 陈晓兰 丁颖[1] 

机构地区：[1]广东药科大学附属第一医院肿瘤科,广东广州510080

出　　处：《临床医学工程》2017年第11期1534-1536,共3页Clinical Medicine & Engineering

摘　　要：目的分析EGFR-TKIs治疗晚期肺腺鳞癌患者的效果。方法选取我院2007年1月至2013年12月收治的34例晚期肺腺鳞癌患者,比较不同基因突变状态患者接受TKI治疗的有效率及PFS,采用Kaplan-Meier法进行生存分析。结果 EGFR基因突变率为47.1%(16/34)。基因突变患者使用EGFR-TKIs的有效率和疾病控制率分别为38.5%和100.0%;而野生型患者的有效率和疾病控制率分别为0.0%和37.5%。EGFR基因突变型与野生型患者的中位PFS分别为15.3个月和1.9个月(P=0.004)。结论 EGFR-TKIs治疗EGFR基因突变的晚期肺腺鳞癌患者效果较好,应对晚期肺腺鳞癌患者常规行EGFR基因突变检测。Objective To analyze the effect of EGFR-TKIs in the treatment of patients with advanced adenosquamous carcinoma of the lung. Methods 34 cases of patients with advanced adenosquamous carcinoma of the lung in our hospital from January 2007 to December 2013 were selected. The effective rate and PFS of TKI treatment were compared among patients with different gene states. Results The EGFR mutation rate was 47.1%. The effective rate and disease control rate in EGFR-mutated patients with EGFR-TKIs were 38.5% and 100.0% respectively. The effective rate and disease control rate in EGFR wild-type patients were 0.0% and 37.5% respectively. The median PFS of EGFR-mutated and EGFR wild-type patients were respectively 15.3 months and 1.9 months （P= 0.004）. Conclusions EGFR-TKIs in the treatment of EGFR-mutated patients with advanced adenosquamous carcinoma of the lung has better effect. EGFR mutation detection should be performed routinely in patients with advanced adenosquamous carcinoma of the lung.

关 键 词：腺鳞癌 表皮生长因子受体 酪氨酸激酶抑制剂 

分 类 号：R734.2[医药卫生—肿瘤]